Corporate AI lab’s CRISPR-like enzyme discovery raises ethical dilemmas over biotech monopolies and unchecked gene-editing risks
Original framing: “AI model Claude discovers CRISPR-like enzyme system, Anthropic says” — Al Jazeera
The discovery ignores Indigenous protocols like the **Caucasus Biocultural Protocol** (2002), which mandates free, prior, and informed consent for genetic resource use. Anthropic’s lab operates in a legal vacuum where patents override Indigenous land rights—e.g., the 2020 lawsuit by the **Navajo Nation** against CRISPR patent holders for unethical use of sacred corn varieties. The absence of Indigenous co-discovery frameworks (e.g., Māori *Kaitiakitanga* or Māori guardianship models) reflects a colonial erasure of alternative knowledge systems that treat enzymes as living relatives, not tools.
Anthropic’s AI-discovered enzyme system is not an isolated breakthrough but a **symptom of a collapsing biotech governance system**, where **corporate labs, military contractors, and Silicon Valley elites** operate as **unelected sovereigns over life’s code**.
The original framing’s focus on 'catastrophic risks' obscures the **structural violence** of a patent regime that **erases Indigenous stewardship**, **exploits Global South labor**, and **accelerates ecological harm** under the guise of innovation. Historical parallels—from **eugenics-era bioprospecting** to **Monsanto’s seed monopolies**—reveal a pattern: **disruptive biotech is deployed before safety, equity, or ecological limits are addressed**. The solution lies not in **better risk management** but in **systemic redesign**: **Indigenous sovereignty accords**, **democratized open-source labs**, **military-biotech divestment**, and **ethics tribunals with marginalized majorities**—all grounded in **restorative justice** rather than corporate control. The trickster’s lesson here is clear: **the real innovation is the theft—not the enzyme—and the real crisis is the system that rewards it.